by No. Retatrutide is not FDA approved as of October 2026, so there is no approved retatrutide label, monthly price, or refund policy to compare while you work on weight, appetite, cravings, and the number on your scale. Lilly plans to submit its application to the FDA in the first quarter of 2027, and early research found meaningful weight changes in clinical trials, but a submission is not an approval.
If you saw “reta” in an ad or video, the key distinction is simple: retatrutide is still an investigational medicine. That means it is being studied, not offered as an FDA-approved medicine for routine prescribing or sale.
What is retatrutide, and why are people talking about it?
Retatrutide is a peptide that acts on GLP-1, GIP, and glucagon receptors. These are body signals involved in appetite, food intake, and energy use. A 2025 systematic review of randomized trials found greater weight reduction with retatrutide than placebo, while also reporting more stomach-related side effects at higher studied doses.
That research helps explain the attention. It does not turn an investigational product into an approved one. If you are sorting through claims about appetite or cravings, it can help to separate a trial result from a product you can safely obtain through ordinary care.
When could FDA approval happen?
Lilly said in its August 2026 SEC filing that its clinical data package was complete and that it planned to submit a Biologics License Application to the FDA in the first quarter of 2027. Forbes also reported on October 15, 2026 that Lilly planned that first-quarter submission.
Submission is the point at which the company asks the FDA to review the application. It is not a promise of approval or a pharmacy availability date. Until there is an FDA decision, no one can give you a reliable approved-retatrutide timeline.
| Question | Answer as of October 2026 |
|---|---|
| FDA approved? | No. |
| Can it be compounded? | No. FDA says retatrutide cannot be used in compounding under federal law. |
| When might Lilly apply? | Lilly plans a first-quarter 2027 FDA submission. |
| Approved monthly price? | There is none for approved retatrutide because it is not approved for routine sale. |
| Approved refund terms? | There are none for an approved retail retatrutide product. |
Can a doctor prescribe retatrutide now?
No. The FDA says retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition. The FDA also says retatrutide cannot be used in compounding under federal law.
A clinician can help you discuss FDA-approved options that fit your health history and goals. The FDA page identifies semaglutide and tirzepatide as approved-drug ingredients, and Lilly’s filing identifies tirzepatide as Zepbound for obesity in the United States. Lilly also announced that FDA approved the oral GLP-1 Foundayo for adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity.
For a broader look at non-prescription weight-support claims, see this GLP-1 supplement guide. Supplements and prescription medicines are different categories, so a supplement facts panel is not the same thing as an FDA-approved drug label.
Why “research use only” does not make reta a personal-use option
“Research use only” is not an FDA approval, a prescription label, or a quality check for personal use. The FDA warns that companies have sold unapproved drugs containing retatrutide directly to consumers while falsely labeling them for research purposes or not for human consumption. The agency says these products may be of unknown quality and may harm health.
Public Citizen reported in June 2026 that 14 hospitalizations connected to retatrutide had been reported to the FDA adverse-event monitoring system. Its report also described sellers using research-only language while influencers promoted human use. That is a reason to step away from an online offer, not a reason to chase a better-looking label.
Is retatrutide safer or stronger than tirzepatide?
There is no simple winner to declare. Retatrutide trial research and FDA-approved tirzepatide are not the same thing, and the available retatrutide studies do not create a personal safety ranking for you.
The 2025 review found that nausea was more common with retatrutide across studied dose levels. It also found higher rates of some adverse events at higher studied doses. The FDA-approved status of tirzepatide does not mean it is right for every person; a clinician can put your medical history, current medicines, appetite changes, meals, water intake, movement, and scale trend into one plan.
Do not combine retatrutide with tirzepatide or try to switch between them based on online advice. Those are medication decisions that need a clinician who knows your situation.
What about visceral fat, weight gain, and changing scale results?
Retatrutide research measured body weight and waist-related outcomes, but it does not give you a personal promise about visceral fat, a specific scale pattern, or what will happen from week to week. Weight can move for many reasons, including meals, fluids, activity, and routine changes.
A steadier way to prepare for a care conversation is to track a few basics for a week or two: your meals, water, movement, appetite, cravings, sleep, and scale trend. That record can be more useful than reacting to one day’s number. If gut symptoms are part of your routine, this daily gut-wellness routine shows how food, water, and tracking can fit together.
What should you check before acting on a retatrutide offer?
- Check whether the product is FDA approved. As of October 2026, retatrutide is not.
- Do not treat “research use only” as a human-use label.
- For any supplement, read the supplement facts panel, ingredient dose, package options, price, and refund terms before you order.
- For a prescription discussion, bring your current medicine list and your recent meal, water, movement, appetite, cravings, and scale notes.
- Ask a clinician which FDA-approved option, if any, fits your situation.
The bottom line
Retatrutide is not FDA approved or available as an approved routine treatment as of October 2026. The research is why people are watching it, and Lilly’s planned first-quarter 2027 submission is the next major milestone. For now, skip offers built around “reta,” research-only labels, a low price, or a supposed refund promise, and keep your next step focused on approved care and a routine you can realistically follow.
Disclosure: This page is for informational purposes and is not a substitute for personal medical advice.
By the New Life Wellness Guide Editorial Team